VBI Vaccines

Variation Biotechnologies Inc. (VBI), also known as VBI Vaccines Inc., is a biopharmaceutical company, headquartered in

National Research Council of Canada (NRC) to produce a COVID-19 vaccine—VBI-2902.^[1]^[2] In August VBI received CA$56 million from the Government of Canada to prepare its vaccine for clinical trials by the end of 2020.^[1] The company's CEO, Jeff Baxter, said that VBI-2902 is cheaper to produce than other vaccines.^{[citation needed}

]

Background

By 2007, VBI had received financial support from the

Investissement Quebec. The company was originally financed by Clarus Ventures, a global life sciences venture capital firm under then CEO is Jeffrey Leiden, ARCH Venture Partners, 5AM Ventures and other private investors.^[2]

VBI-2902 vaccine

In early 2020, in collaboration with NRC the VBI's vaccine—VBI-2900—was developed. According to the company, they have two vaccine candidates—"enveloped virus-like particle (eVLP)".^[3] VBI-2901 is a "trivalent pan-coronavirus vaccine expressing the SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins". VBI-2902 is a "monovalent COVID-19-specific vaccine expressing the SARS-CoV-2 spike protein".^[3] By March 9, the initial Phase 1/2 study of VBI-2902 was underway.^[3] VBI received CA$56 million from the federal government towards the COVID-19 vaccine development.^[1] The company's CEO, Jeff Baxter, said that VBI-2902 is cheaper to produce than other vaccines.^{[citation needed]}

References

^ ^a ^b ^c "Podcast: Kemptville's next boom, Variation Biotechnologies' $56M injection, Vanier 'gateway'" (Podcast). Behind the Headlines. August 2020. Archived from the original on May 2, 2021. Retrieved March 22, 2021.
^ ^a ^b "Variation Biotechnologies Secures $35.7M in Series A Financing to Fund Innovative Vaccine Platform". VBI Vaccines. January 4, 2007. Retrieved March 22, 2021.
^ ^a ^b ^c "VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902". VBI Vaccines. March 9, 2021. Retrieved March 22, 2021.

External links

Official website

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it.

This article about a Canadian corporation or company is a stub. You can help Wikipedia by expanding it.

This United States corporation or company article is a stub. You can help Wikipedia by expanding it.

[BTH_202008-1] "Podcast: Kemptville's next boom, Variation Biotechnologies' $56M injection, Vanier 'gateway'" (Podcast). Behind the Headlines. August 2020. Archived from the original on May 2, 2021. Retrieved March 22, 2021.

[vbivaccines_20070104-2] "Variation Biotechnologies Secures $35.7M in Series A Financing to Fund Innovative Vaccine Platform". VBI Vaccines. January 4, 2007. Retrieved March 22, 2021.

[VBI_vaccines_20210309-3] "VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902". VBI Vaccines. March 9, 2021. Retrieved March 22, 2021.

[1]

[2]

[3]